Long-term outcomes of percutaneous left atrial appendage closure for the prevention of stroke in patients with atrial fibrillation: Asia-Pacific experience

Lam, 2012, Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience, Cathet Cardiovasc Interv, 79, 794, 10.1002/ccd.23136 Lubitz, 2017, Stroke as the initial manifestation of atrial fibrillation: the Framingham Heart study, Stroke, 48, 490, 10.1161/STROKEAHA.116.015071 Chiang, 2016, 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation, J Formos Med Assoc, 115, 893, 10.1016/j.jfma.2016.10.005 Yao, 2017, Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation, Am J Cardiol, 120, 1549, 10.1016/j.amjcard.2017.07.051 Fang, 2007, Death and disability from warfarin-associated intracranial and extracranial hemorrhages, Am J Med, 120, 700, 10.1016/j.amjmed.2006.07.034 Cruz-Gonzalez, 2010, Left atrial appendage exclusion: state-of-the-art, Cathet Cardiovasc Interv, 75, 806, 10.1002/ccd.22344 Holmes, 2009, Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial, Lancet, 374, 534, 10.1016/S0140-6736(09)61343-X Reddy, 2014, Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial, J Am Med Assoc, 312, 1988, 10.1001/jama.2014.15192 Park, 2011, Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience, Cathet Cardiovasc Interv, 77, 700, 10.1002/ccd.22764 Nietlispach, 2013, Amplatzer left atrial appendage occlusion: single center 10-year experience, Cathet Cardiovasc Interv, 82, 283, 10.1002/ccd.24872 Tzikas, 2016, Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug, EuroIntervention, 11, 1170, 10.4244/EIJY15M01_06 Landmesser, 2017, Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study, EuroIntervention, 13, 867, 10.4244/EIJ-D-17-00493 Berti, 2017, Left atrial appendage closure using AMPLATZER devices: a large, multicenter, Italian registry, Int J Cardiol, 248, 103, 10.1016/j.ijcard.2017.07.052 Lam, 2012, The pharmacogenetics of the response to warfarin in Chinese, Br J Clin Pharmacol, 73, 340, 10.1111/j.1365-2125.2011.04097.x Chen, 2015, Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study, PLoS One, 10 Lee, 2019, Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation, Stroke, 50, 2245, 10.1161/STROKEAHA.119.025536 Shen, 2007, Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation, J Am Coll Cardiol, 50, 309, 10.1016/j.jacc.2007.01.098 Hori, 2013, Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation, Stroke, 44, 1891, 10.1161/STROKEAHA.113.000990 Wong, 2014, Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial, Stroke, 45, 1739, 10.1161/STROKEAHA.113.002968 Goto, 2014, Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial, Am Heart J, 168, 303, 10.1016/j.ahj.2014.06.005 Yamashita, 2016, Edoxaban vs. Warfarin in East Asian patients with atrial fibrillation- an ENGAGE AF-TIMI 48 subanalysis, Circ J, 80, 860, 10.1253/circj.CJ-15-1082 Holmes, 2014, Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial, J Am Coll Cardiol, 64, 1, 10.1016/j.jacc.2014.04.029 Tzikas, 2016, Left atrial appendage occlusion with the AMPLATZER Amulet device: an expert consensus step-by-step approach, EuroIntervention, 11, 1512, 10.4244/EIJV11I13A292 Fountain, 2006, The PROTECT AF (WATCHMAN left atrial appendage system for embolic PROTECTion in patients with atrial fibrillation) trial, Am Heart J, 151, 956, 10.1016/j.ahj.2006.02.005 Viles-Gonzalez, 2012, J Am Coll Cardiol, 59, 923, 10.1016/j.jacc.2011.11.028 Reddy, 2017, 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials, J Am Coll Cardiol, 70, 2964, 10.1016/j.jacc.2017.10.021 Boersma, 2019, Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure Technology, Circ Arrhythm Electrophysiol, 12, 10.1161/CIRCEP.118.006841 Phillips, 2019, Left atrial appendage closure with WATCHMAN in Asian patients: 2 year outcomes from the WASP registry, Int J Cardiol Heart Vasc, 23, 100358 Kim, 2016, Left atrial appendage occlusion in non-valvular atrial fibrillation in a Korean multi-center registry, Circ J, 80, 1123, 10.1253/circj.CJ-15-1134 Lee, 2018, Feasibility of left atrial appendage occlusion for left atrial appendage thrombus in patients with persistent atrial fibrillation, Am J Cardiol, 121, 1534, 10.1016/j.amjcard.2018.02.045 Zhai, 2019, Experience of left atrial appendage occlusion with the WATCHMAN device in Chinese patients, Anatol J Cardiol, 21, 314 Bergmann, 2017, Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry, EuroIntervention, 13, 877, 10.4244/EIJ-D-17-00042 Pracon, 2018, Device thrombosis after percutaneous left atrial appendage occlusion is related to patient and procedural characteristics but not to duration of postimplantation dual antiplatelet therapy, Circ Cardiovasc Interv, 11, 10.1161/CIRCINTERVENTIONS.117.005997 Fauchier, 2018, Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation, J Am Coll Cardiol, 71, 1528, 10.1016/j.jacc.2018.01.076 Alkhouli, 2018, Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis, JACC Clin Electrophysiol, 4, 1629, 10.1016/j.jacep.2018.09.007 Price, 2014, Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium, J Am Coll Cardiol, 64, 565, 10.1016/j.jacc.2014.03.057 Lee, 2016, A randomized, prospective pilot comparison of 3 atrial appendage elimination techniques: internal ligation, stapled excision, and surgical excision, J Thorac Cardiovasc Surg, 152, 1075, 10.1016/j.jtcvs.2016.06.009 Staubach, 2019, Long-term transesophageal echocardiography follow-up after percutaneous left atrial appendage closure, Heart Rhythm, 175, 728 Garot, 2019, Device-related thrombus after left atrial appendage closure, Intervent Cardiol, 14, 42, 10.15420/icr.2018.21.3 Chan, 2015, Experience of left atrial appendage closure performed under conscious sedation, Asian Cardiovasc Thorac Ann, 23, 394, 10.1177/0218492314548231 Matsuo, 2016, Left atrial appendage closure under intracardiac echocardiographic guidance: feasibility and comparison with transesophageal echocardiography, J Am Heart Assoc, 5, 10.1161/JAHA.116.003695 Tilz, 2017, Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey, Europace, 19, 1737, 10.1093/europace/eux254 Hemam, 2019, Left atrial appendage closure with the Watchman device using intracardiac vs transesophageal echocardiography: procedural and cost considerations, Heart Rhythm, 16, 334, 10.1016/j.hrthm.2018.12.013